PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542851
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1542851
Global CRISPR Based Diagnostics Market - 2024-2031
Overview
Global CRISPR-Based Diagnostics Market reached US$ 3.5 billion in 2023 and is expected to reach US$ 10.6 billion by 2031, growing at a CAGR of 15.5% during the forecast period 2024-2031.
CRISPR-based diagnostics have emerged as promising tools capable of revolutionizing the field of molecular diagnostics. CRISPR enzymes can be useful in biomedical applications to recognize biomarkers of infectious and non-infectious diseases, as well as cancer and many other diseases that involve a nucleic acid sequence.
In CRISPR-based diagnostics, the most commonly used isothermal amplification methods are RPA and LAMP. CRISPR is changing diagnostics, as researchers are leveraging the search function of CRISPR to detect specific DNA and RNA sequences in samples.
Market Dynamics: Drivers & Restraints
Rising incidence of infectious diseases
Developing rapid and sensitive diagnostic tools is key for successful patient management and curbing disease spread. With the rapid increase in diseases, there is a surge in the demand for rapid diagnostic tools and methods. For instance, in 2024, the CDC estimated that there have been at least 35 million illnesses, 400,000 hospitalizations, and 25,000 deaths from flu so far this season.
Currently, available diagnostics are very specific and sensitive but time-consuming and require expensive laboratory settings and well-trained personnel, thus, they are not available in resource-limited areas, for large-scale screenings, and in case of outbreaks and epidemics.
Additionally, dengue is a viral infection transmitted to humans through the bite of infected mosquitoes. About half of the world's population is at risk of dengue with an estimated 100-400 million infections occurring each year. Timely diagnosis is crucial for effective patient management and outbreak control of infectious diseases.
CRISPR-based diagnostics can provide rapid and accurate results, allowing healthcare providers to make informed decisions quickly. CRISPR technologies can offer high specificity and sensitivity in detecting the dengue virus, enabling the differentiation between dengue and other similar diseases. Thus, the above factors are expected to drive the market growth.
Increased costs of CRISPR-based diagnostics
The process of creating CRISPR-based diagnosis often involves costly regulatory approvals, in-depth testing, and sophisticated research. Tests may become less cost-effective as a result of these high expenses getting passed on to customers. This could impact the market growth negatively.
Segment Analysis
The global CRISPR-based diagnostics market is segmented based on technique, product, disease, end-user, and region.
Recombinase Polymerase Amplification (RPA) segment is expected to dominate the market share
The recombinase polymerase amplification segment is expected to hold a significant share in the market growth. To develop quick and precise diagnostic tests, RPA can be easily combined with CRISPR-based systems. The combination makes it possible to identify diseases or mutations precisely by detecting particular genomic sequences.
RPA technology applies to point-of-care testing and is quite simple. This is particularly crucial in remote or resource-constrained environments where conventional lab facilities might not be accessible. RPA is usually cheaper than alternative amplification techniques, which lowers the total cost of diagnostic testing.
Its acceptance in markets that are developed as well as developing may be driven by its cost. Thus, the rate of adoption is higher for the technology, therefore holding a dominant position in the market share.
Geographical Analysis
North America is expected to hold a significant position in the CRISPR-based diagnostics market share
In North America, there are a lot of collaborations between government agencies, commercial businesses, and academic institutions. These alliances promote creativity and quicken the process of turning research into useful applications. The COVID-19 epidemic has brought attention to the growing need for quick and precise diagnostic instruments. Healthcare professionals consider CRISPR-based diagnostics to be appealing as they provide accurate and timely results.
The increasing number of chronic diseases, genetic disorders, and infectious diseases in the region is increasing the demand for new and efficient diagnostic methods. For instance, Centers for Disease Control & Prevention stated that during 2023, a total of 9,615 TB cases were provisionally reported by the 50 U.S. states and the District of Columbia (DC), representing an increase of 1,295 cases (16%) as compared with 2022.
With the rising prevalence and incidence of infectious and non-infectious diseases, researchers are finding better diagnostic tools such as CRISPR-based diagnostics and methods to provide accurate and efficient diagnostic methods. The rising number of diseases will increase the demand for CRISPR-based diagnostics. This is expected to drive the market growth during the forecast period.
Market Segmentation
By Technique
Recombinase Polymerase Amplification (RPA)
Loop-mediated Isothermal Amplification (LAMP)
Others
By Product
Kits
Buffer Solutions
Software
Others
By Disease
Infectious Diseases
Bacterial Infectious Diseases
Parasitic Infectious Diseases
Viral Infections
Others
Non-Infectious Diseases
Cardiovascular Diseases
Genetic Disorders
Cancers
Others
By End-User
Hospitals
Diagnostic Centers
Biotechnology Companies
Academic and Research Institutes
Others
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Competitive Landscape
The major global players in the market include Sherlock Biosciences, Mammoth Biosciences, TwistDx Limited, G-Biosciences, CasZyme, Integrated DNA Technologies, Inc., and CRISPR Diagnostics among others.
Why Purchase the Report?
To visualize the global CRISPR-based diagnostics market segmentation based on technique, product, disease, end-user, and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of CRISPR-based diagnostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.
The global CRISPR-based diagnostics market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2023
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Technique
- 3.2. Snippet by Product
- 3.3. Snippet by Disease
- 3.4. Snippet by End-User
- 3.5. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising Prevalence and Incidence of Infectious Diseases
- 4.1.2. Restraints
- 4.1.2.1. Increased Costs of CRISPR Based Diagnostics
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
6. By Technique
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
- 6.1.2. Market Attractiveness Index, By Technique
- 6.2. Recombinase Polymerase Amplification (RPA)*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Loop-mediated Isothermal Amplification (LAMP)
- 6.4. Others
7. By Product
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
- 7.2. Kits*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Buffer Solutions
- 7.4. Software
- 7.5. Others
8. By Disease
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
- 8.1.2. Market Attractiveness Index, By Disease
- 8.2. Infectious Diseases*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. Bacterial Infectious Diseases
- 8.2.4. Parasitic Infectious Diseases
- 8.2.5. Viral Infections
- 8.2.6. Others
- 8.3. Non-Infectious Diseases
- 8.3.1. Cardiovascular Diseases
- 8.3.2. Genetic Disorders
- 8.3.3. Cancers
- 8.3.4. Others
9. By End-User
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Diagnostic Centers
- 9.4. Biotechnology Companies
- 9.5. Academic and Research Institutes
- 9.6. Others
10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
- 10.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
- 10.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.3.1. The U.S.
- 10.2.3.2. Canada
- 10.2.3.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
- 10.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.4.1. Germany
- 10.3.4.2. UK
- 10.3.4.3. France
- 10.3.4.4. Italy
- 10.3.4.5. Spain
- 10.3.4.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
- 10.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.4.1. Brazil
- 10.4.4.2. Argentina
- 10.4.4.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
- 10.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.4.1. China
- 10.5.4.2. India
- 10.5.4.3. Japan
- 10.5.4.4. South Korea
- 10.5.4.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
- 10.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease
- 10.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
12. Company Profiles
- 12.1. Sherlock Biosciences*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Mammoth Biosciences
- 12.3. TwistDx Limited
- 12.4. G-Biosciences
- 12.5. CasZyme
- 12.6. Integrated DNA Technologies, Inc.
- 12.7. CRISPR Diagnostics
LIST NOT EXHAUSTIVE
13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
